Gastrointestinal stromal tumours (GISTs) represent 0.1-3% of all neoplasms of the digestive tract and only in 1-2% of cases they arise in the esophagus. The most frequent clinical manifestations of esophageal GISTs (E-GISTs) are dysphagia, atypical chest pain, cough or gastrointestinal bleeding. Preoperative study is made by endoscopy, echo-endoscopy, biopsy and computed tomography or magnetic resonance imaging. The preoperative diagnosis is difficult because only histological examination can differentiate them from other esophageal tumours (as leiomyoma, schwannoma and leiomyosarcoma) and rarely a biopsy is performed at a submucosal well-circumscribed esophageal mass. Surgery is the first choice approach for localized and resectable cases. Thoracoscopic or laparoscopic enucleation is sufficient for small-sized and well-capsulated tumours, instead, esophagectomy should be considered in all other cases. Imatinib is the drug of choice for pharmacologic treatment in advanced disease. We report our anecdotal experience of a 63-year old male patient presented at our Unit complaining of dysphagia and underwent transhiatal laparoscopic enucleation of E-GIST.
Published in | International Journal of Cardiovascular and Thoracic Surgery (Volume 2, Issue 1) |
DOI | 10.11648/j.ijcts.20160201.11 |
Page(s) | 1-4 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2016. Published by Science Publishing Group |
Gastrointestinal Stromal Tumours, Esophageal Neoplasms, Dysphagia, Laparoscopy
[1] | Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor. Am J Surg. 2007 Aug; 194(2): 148-52. |
[2] | Iannicelli E, Sapori A, Panzuto F, Pilozzi E, Delle Fave G, David V. Oesophageal GIST: MDCT Findings of Two Cases and Review of the Literature. J Gastrointest Cancer. 2012 Sep; 43(3): 481-5. |
[3] | Blum MG, Bilimoria KY, Wayne JD, de Hoyos AL, Talamonti MS, Adley B. Surgical Considerations for the Management and Resection of Esophageal Gastrointestinal Stromal Tumors. Ann Thorac Surg. 2007 Nov; 84(5): 1717-23. |
[4] | Lee HJ, Park SI, Kim DK, Kim YH. Surgical Resection of Esophageal Gastrointestinal Stromal Tumors. Ann Thorac Surg. 2009 May; 87(5): 1569-71. |
[5] | Al-Salam S, El-Teraifi HA, Taha MS. Could imatinib replace surgery in esophageal gastrointestinal stromal tumor. Saudi Med J. 2006 Aug; 27(8): 1236-9. |
[6] | Rösch T, Kapfer B, Will U, Baronius W, Strobel M, Lorenz R, Ulm K. Accuracy of Endoscopic Ultrasonography in Upper Gastrointestinal Submucosal Lesions: a Prospective Multicenter Study. Scand J Gastroenterol. 2002 Jul; 37(7): 856-62. |
[7] | Coccolini F, Catena F, Ansaloni L, Lazzareschi D, Pinna AD. Esophagogastric junction gastrointestinal stromal tumor: Resection vs enucleation. World J Gastroenterol. Sep 21, 2010; 16(35): 4374–4376. |
[8] | Peparini N, Carbotta G, Chirletti P. Enucleation for gastrointestinal stromal tumors at the esophagogastric junction: Is this an adequate solution? World J Gastroenterol. 2011 Apr 28; 17(16): 2159-60. |
[9] | Cukier M, Bailey G, Rodríguez-Zentner HA. Clinical image in gastroenterology. Thoracoscopic enucleation of esophageal GIST. Rev Gastroenterol Mex. 2009; 74(1): 50-1. |
[10] | Nishida T, Kawai N, Yamaguchi S, Nishida Y. Submucosal tumors: Comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors. Digestive Endoscopy 2013; 25: 479–489. |
APA Style
Antonello Cuttitta, Antonio Tancredi, Roberto Scaramuzzi, Paola Parente, Gerardo Scaramuzzi, et al. (2016). Esophageal Gastrointestinal Stromal Tumour: A Case Report. International Journal of Cardiovascular and Thoracic Surgery, 2(1), 1-4. https://doi.org/10.11648/j.ijcts.20160201.11
ACS Style
Antonello Cuttitta; Antonio Tancredi; Roberto Scaramuzzi; Paola Parente; Gerardo Scaramuzzi, et al. Esophageal Gastrointestinal Stromal Tumour: A Case Report. Int. J. Cardiovasc. Thorac. Surg. 2016, 2(1), 1-4. doi: 10.11648/j.ijcts.20160201.11
@article{10.11648/j.ijcts.20160201.11, author = {Antonello Cuttitta and Antonio Tancredi and Roberto Scaramuzzi and Paola Parente and Gerardo Scaramuzzi and Marco Taurchini}, title = {Esophageal Gastrointestinal Stromal Tumour: A Case Report}, journal = {International Journal of Cardiovascular and Thoracic Surgery}, volume = {2}, number = {1}, pages = {1-4}, doi = {10.11648/j.ijcts.20160201.11}, url = {https://doi.org/10.11648/j.ijcts.20160201.11}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcts.20160201.11}, abstract = {Gastrointestinal stromal tumours (GISTs) represent 0.1-3% of all neoplasms of the digestive tract and only in 1-2% of cases they arise in the esophagus. The most frequent clinical manifestations of esophageal GISTs (E-GISTs) are dysphagia, atypical chest pain, cough or gastrointestinal bleeding. Preoperative study is made by endoscopy, echo-endoscopy, biopsy and computed tomography or magnetic resonance imaging. The preoperative diagnosis is difficult because only histological examination can differentiate them from other esophageal tumours (as leiomyoma, schwannoma and leiomyosarcoma) and rarely a biopsy is performed at a submucosal well-circumscribed esophageal mass. Surgery is the first choice approach for localized and resectable cases. Thoracoscopic or laparoscopic enucleation is sufficient for small-sized and well-capsulated tumours, instead, esophagectomy should be considered in all other cases. Imatinib is the drug of choice for pharmacologic treatment in advanced disease. We report our anecdotal experience of a 63-year old male patient presented at our Unit complaining of dysphagia and underwent transhiatal laparoscopic enucleation of E-GIST.}, year = {2016} }
TY - JOUR T1 - Esophageal Gastrointestinal Stromal Tumour: A Case Report AU - Antonello Cuttitta AU - Antonio Tancredi AU - Roberto Scaramuzzi AU - Paola Parente AU - Gerardo Scaramuzzi AU - Marco Taurchini Y1 - 2016/05/05 PY - 2016 N1 - https://doi.org/10.11648/j.ijcts.20160201.11 DO - 10.11648/j.ijcts.20160201.11 T2 - International Journal of Cardiovascular and Thoracic Surgery JF - International Journal of Cardiovascular and Thoracic Surgery JO - International Journal of Cardiovascular and Thoracic Surgery SP - 1 EP - 4 PB - Science Publishing Group SN - 2575-4882 UR - https://doi.org/10.11648/j.ijcts.20160201.11 AB - Gastrointestinal stromal tumours (GISTs) represent 0.1-3% of all neoplasms of the digestive tract and only in 1-2% of cases they arise in the esophagus. The most frequent clinical manifestations of esophageal GISTs (E-GISTs) are dysphagia, atypical chest pain, cough or gastrointestinal bleeding. Preoperative study is made by endoscopy, echo-endoscopy, biopsy and computed tomography or magnetic resonance imaging. The preoperative diagnosis is difficult because only histological examination can differentiate them from other esophageal tumours (as leiomyoma, schwannoma and leiomyosarcoma) and rarely a biopsy is performed at a submucosal well-circumscribed esophageal mass. Surgery is the first choice approach for localized and resectable cases. Thoracoscopic or laparoscopic enucleation is sufficient for small-sized and well-capsulated tumours, instead, esophagectomy should be considered in all other cases. Imatinib is the drug of choice for pharmacologic treatment in advanced disease. We report our anecdotal experience of a 63-year old male patient presented at our Unit complaining of dysphagia and underwent transhiatal laparoscopic enucleation of E-GIST. VL - 2 IS - 1 ER -